KATP channel openers for the treatment of airways hyperreactivity.
Buchheit
K H
KH
Department of Research, Novartis Pharma AG, CH-4002 Basel, Switzerland.
Fozard
J R
JR
D000255:Adenosine Triphosphate / Q000378:metabolism; D000818:Animals; D001249:Asthma / Q000188:drug therapy*; D016535:Bronchial Hyperreactivity / Q000188:drug therapy*; D016084:Bronchoconstriction / Q000187:drug effects*; D001993:Bronchodilator Agents / Q000494:pharmacology / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D015221:Potassium Channels / Q000187:drug effects*
D001993:Bronchodilator Agents; D015221:Potassium Channels; D000255:Adenosine Triphosphate